1. Home
  2. CNTB vs KZR Comparison

CNTB vs KZR Comparison

Compare CNTB & KZR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CNTB
  • KZR
  • Stock Information
  • Founded
  • CNTB 2012
  • KZR 2015
  • Country
  • CNTB United States
  • KZR United States
  • Employees
  • CNTB N/A
  • KZR N/A
  • Industry
  • CNTB Biotechnology: Pharmaceutical Preparations
  • KZR Biotechnology: Pharmaceutical Preparations
  • Sector
  • CNTB Health Care
  • KZR Health Care
  • Exchange
  • CNTB Nasdaq
  • KZR Nasdaq
  • Market Cap
  • CNTB 44.2M
  • KZR N/A
  • IPO Year
  • CNTB 2021
  • KZR 2018
  • Fundamental
  • Price
  • CNTB N/A
  • KZR $4.58
  • Analyst Decision
  • CNTB Strong Buy
  • KZR Hold
  • Analyst Count
  • CNTB 2
  • KZR 2
  • Target Price
  • CNTB $7.50
  • KZR $9.00
  • AVG Volume (30 Days)
  • CNTB 103.1K
  • KZR 44.2K
  • Earning Date
  • CNTB 05-15-2025
  • KZR 08-12-2025
  • Dividend Yield
  • CNTB N/A
  • KZR N/A
  • EPS Growth
  • CNTB N/A
  • KZR N/A
  • EPS
  • CNTB N/A
  • KZR N/A
  • Revenue
  • CNTB $26,033,000.00
  • KZR N/A
  • Revenue This Year
  • CNTB N/A
  • KZR N/A
  • Revenue Next Year
  • CNTB N/A
  • KZR N/A
  • P/E Ratio
  • CNTB N/A
  • KZR N/A
  • Revenue Growth
  • CNTB N/A
  • KZR N/A
  • 52 Week Low
  • CNTB $0.51
  • KZR $3.62
  • 52 Week High
  • CNTB $1.60
  • KZR $9.18
  • Technical
  • Relative Strength Index (RSI)
  • CNTB 72.64
  • KZR 54.77
  • Support Level
  • CNTB $1.02
  • KZR $4.28
  • Resistance Level
  • CNTB $1.07
  • KZR $4.80
  • Average True Range (ATR)
  • CNTB 0.09
  • KZR 0.33
  • MACD
  • CNTB 0.01
  • KZR 0.01
  • Stochastic Oscillator
  • CNTB 91.19
  • KZR 67.44

About CNTB Connect Biopharma Holdings Limited

Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.

Share on Social Networks: